Boundless Bio (BOLD) Announces Pipeline and Leadership Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
Boundless Bio Announces Pipeline and Leadership Updates
December 12, 2024 4:01 PM ESTCompany elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial
Third ecDTx program advancing, with plans for development candidate nomination by mid-2025
Operating runway extended into 2027, through anticipated clinical readout for BBI-355 and key development milestones for third ecDTx program
Klaus Wagner, M.D., Ph.D., Chief Medical Officer, and Neil Abdollahian, Chief Business Officer, stepping down; James L. Freddo, M.D., to serve as Interim Chief Medical Officer
SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) --... More
